Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • dólar/libra

    1.2637
    +0.0015 (+0.12%)
     
  • USD/JPY

    151.2390
    -0.1330 (-0.09%)
     
  • Bitcoin USD

    70,071.23
    -1,289.85 (-1.81%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Could Sinovac Biotech Be The Next Ebola Play?

In light of the recent Ebola scare, many related stocks have experienced strong upside in the past month.

Lakeland Industries (NASDAQ: LAKE) up 248 percent, last at $25.01.
Alpha Pro Tech, Ltd. (NYSE: APT) up 233 percent, last at $9.17.
Ibio Inc (NYSE: IBIO) up 124 percent, last at $1.38.
Chimeric Inc (NASDAQ: CMRX) up 20 percent, last at $31.64.

Sinovac Biotech Ltd. (NASDAQ: SVA) is an integrated China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases.

Benzinga reached out to the director of Investor Relations at Sinovac, Helen Yang to inquire about the company’s direction and if they may be entering the Ebola space.

Yang replied, stating, "Currently, we do not have a plan to develop an Ebola vaccine."

Shares of Sinovac were last up up 3.8 percent at $5.25.

See more from Benzinga

© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement